Benitec Biopharma Inc.
BNTC
$12.37
-$0.63-4.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | 100.00% |
| Gross Profit | -- | -- | -- | -- | -100.00% |
| SG&A Expenses | 87.77% | 222.93% | 347.07% | 328.49% | 192.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.92% | 111.87% | 137.06% | 118.35% | 74.33% |
| Operating Income | -43.92% | -111.87% | -137.06% | -118.35% | -74.39% |
| Income Before Tax | -44.49% | -117.92% | -135.74% | -108.08% | -55.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.49% | -117.92% | -135.74% | -108.08% | -55.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.49% | -117.92% | -135.74% | -108.08% | -55.97% |
| EBIT | -43.92% | -111.87% | -137.06% | -118.35% | -74.39% |
| EBITDA | -44.07% | -112.40% | -137.81% | -118.90% | -74.69% |
| EPS Basic | -11.15% | -45.24% | 61.68% | 80.24% | 88.62% |
| Normalized Basic EPS | -8.89% | -41.83% | 61.04% | 78.91% | 87.99% |
| EPS Diluted | -11.15% | -45.24% | 61.68% | 80.24% | 88.62% |
| Normalized Diluted EPS | -8.89% | -41.83% | 61.04% | 78.91% | 87.99% |
| Average Basic Shares Outstanding | 37.41% | 53.09% | 112.60% | 196.66% | 425.40% |
| Average Diluted Shares Outstanding | 37.41% | 53.09% | 112.60% | 196.66% | 425.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |